<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Ther</journal-id>
<journal-title-group>
<journal-title>Molecular Therapy</journal-title>
</journal-title-group>
<issn pub-type="ppub">1525-0016</issn>
<issn pub-type="epub">1525-0024</issn>
<publisher>
<publisher-name>American Society of Gene &amp; Cell Therapy</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30196853</article-id>
<article-id pub-id-type="pmc">6127971</article-id>
<article-id pub-id-type="publisher-id">S1525-0016(18)30258-2</article-id>
<article-id pub-id-type="doi">10.1016/j.ymthe.2018.05.025</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Retinal AAV8-<italic>RS1</italic> Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Cukras</surname>
<given-names>Catherine</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wiley</surname>
<given-names>Henry E.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jeffrey</surname>
<given-names>Brett G.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sen</surname>
<given-names>H. Nida</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Turriff</surname>
<given-names>Amy</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zeng</surname>
<given-names>Yong</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vijayasarathy</surname>
<given-names>Camasamudram</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marangoni</surname>
<given-names>Dario</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ziccardi</surname>
<given-names>Lucia</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kjellstrom</surname>
<given-names>Sten</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Park</surname>
<given-names>Tae Kwon</given-names>
</name>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hiriyanna</surname>
<given-names>Suja</given-names>
</name>
<xref ref-type="aff" rid="aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wright</surname>
<given-names>J. Fraser</given-names>
</name>
<xref ref-type="aff" rid="aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Colosi</surname>
<given-names>Peter</given-names>
</name>
<xref ref-type="aff" rid="aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Zhijian</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bush</surname>
<given-names>Ronald A.</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Lisa L.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sieving</surname>
<given-names>Paul A.</given-names>
</name>
<email>paulsieving@nei.nih.gov</email>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="cor1">∗</xref>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label>NIH, National Eye Institute, Bethesda, MD 20892, USA</aff>
<aff id="aff2"><label>2</label>STRRMD/NIDCD/NIH, Bethesda, MD 20874, USA</aff>
<aff id="aff3"><label>3</label>Neurophysiology of Vision and Neuropathmology Unit, IRCCS Fondazione G.B. Bietti, Rome 00198, Italy</aff>
<aff id="aff4"><label>4</label>Department of Ophthalmology, Lund University, Lund, Sweden</aff>
<aff id="aff5"><label>5</label>Ophthalomology, Soonchunhyang University Bucheon Hospital, Seoul, Korea</aff>
<aff id="aff6"><label>6</label>Ocular Gene Therapy Core, National Eye Institute, Bethesda, MD 20892, USA</aff>
<aff id="aff7"><label>7</label>Ophthalomology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA</aff>
<author-notes>
<corresp id="cor1"><label>∗</label>Corresponding author: Paul A. Sieving, NIH, National Eye Institute, 31 Center Drive, Building 31 room 6A03, Bethesda, MD 20892, USA. <email>paulsieving@nei.nih.gov</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>05</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>07</day>
<month>7</month>
<year>2018</year>
</pub-date>
<volume>26</volume>
<issue>9</issue>
<fpage>2282</fpage>
<lpage>2294</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>4</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>5</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder></copyright-holder>
</permissions>
<related-article ext-link-type="doi" id="d31e12" related-article-type="article-reference" xlink:href="10.1016/j.ymthe.2018.08.003"></related-article>
<abstract id="abs0010">
<p>This study evaluated the safety and tolerability of ocular <italic>RS1</italic> adeno-associated virus (AAV8-<italic>RS1</italic>) gene augmentation therapy to the retina of participants with X-linked retinoschisis (XLRS). XLRS is a monogenic trait affecting only males, caused by mutations in the <italic>RS1</italic> gene. Retinoschisin protein is secreted principally in the outer retina, and its absence results in retinal cavities, synaptic dysfunction, reduced visual acuity, and susceptibility to retinal detachment. This phase I/IIa single-center, prospective, open-label, three-dose-escalation clinical trial administered vector to nine participants with pathogenic <italic>RS1</italic> mutations. The eye of each participant with worse acuity (≤63 letters; Snellen 20/63) received the AAV8-<italic>RS1</italic> gene vector by intravitreal injection. Three participants were assigned to each of three dosage groups: 1e9 vector genomes (vg)/eye, 1e10 vg/eye, and 1e11 vg/eye. The investigational product was generally well tolerated in all but one individual. Ocular events included dose-related inflammation that resolved with topical and oral corticosteroids. Systemic antibodies against AAV8 increased in a dose-related fashion, but no antibodies against RS1 were observed. Retinal cavities closed transiently in one participant. Additional doses and immunosuppressive regimens are being explored to pursue evidence of safety and efficacy (ClinicalTrials.gov: <ext-link ext-link-type="uri" id="intref0010" xlink:href="ctgov:NCT02317887">NCT02317887</ext-link>).</p>
</abstract>
<kwd-group id="kwrds0010">
<title>Keywords</title>
<kwd>gene therapy</kwd>
<kwd>X-linked retinoschisis</kwd>
<kwd>clinical trial</kwd>
<kwd>AAV vector</kwd>
<kwd>ocular disease</kwd>
<kwd>retinal disease</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>